\begin{tabular*}{\textwidth}{@{\extracolsep\fill}clllllllllll@{\extracolsep\fill}}
\toprule
&  & \multicolumn{3}{c}{Final Selection (\%)$^1$} & \multicolumn{3}{c}{Allocations (\%)} & &  &  &  \\
\multirow{2}{2em}{Alpha} & \multirow{2}{2em}{Method} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{Toxic~\%$^2$} & \multirow{2}{2em}{DLTs} & \multirow{2}{2em}{Trial Size} & \multirow{2}{2em}{Days}  \\ \\ 
\midrule
\multirow{4}{2em}{0} & CRM & 42 & 15 & 43 & 26 & 23 & 51 & 23 & 7.0 & 28.2 & 406\\
 & AIDE-CRM & 40 & 16 & 44 & 26 & 23 & 52 & 23 & 6.9 & 24.4 & 352\\
 & $\alpha$-CRM & 43 & 19 & 38 & 26 & 25 & 49 & 25 & 7.2 & 24.2 & 349\\
 & IPDE-POCRM & 46 & 23 & 31 & 27 & 27 & 46 & 27 & 7.5 & 23.5 & 338\\
\midrule
\multirow{4}{2em}{0.3} & CRM & 41 & 16 & 44 & 26 & 23 & 51 & 23 & 7.0 & 28.2 & 406\\
 & AIDE-CRM & 39 & 14 & 47 & 25 & 22 & 53 & 26 & 7.1 & 24.5 & 353\\
 & $\alpha$-CRM & 42 & 18 & 40 & 26 & 24 & 50 & 28 & 7.3 & 24.3 & 349\\
 & IPDE-POCRM & 46 & 21 & 33 & 28 & 26 & 46 & 31 & 7.7 & 23.5 & 339\\
\midrule
\multirow{4}{2em}{0.6} & CRM & 41 & 16 & 44 & 26 & 23 & 51 & 23 & 7.0 & 28.2 & 406\\
 & AIDE-CRM & 37 & 13 & 50 & 24 & 21 & 54 & 26 & 7.2 & 24.6 & 354\\
 & $\alpha$-CRM & 42 & 17 & 41 & 26 & 24 & 50 & 29 & 7.5 & 24.3 & 350\\
 & IPDE-POCRM & 46 & 19 & 35 & 27 & 26 & 47 & 32 & 7.9 & 23.5 & 338\\
\midrule
\multirow{4}{2em}{0.9} & CRM & 41 & 16 & 43 & 26 & 23 & 51 & 23 & 7.0 & 28.2 & 406\\
 & AIDE-CRM & 35 & 12 & 54 & 23 & 21 & 56 & 28 & 7.4 & 24.6 & 355\\
 & $\alpha$-CRM & 41 & 15 & 44 & 25 & 23 & 52 & 31 & 7.8 & 24.4 & 350\\
 & IPDE-POCRM & 44 & 18 & 38 & 27 & 24 & 49 & 34 & 8.1 & 23.5 & 338\\
\bottomrule
\end{tabular*}
